Helus Pharma Inc.

Helus Pharma Inc.

HELP · NEO · Healthcare / Biotechnology

8.73CAD-0.92 (-9.53%)

Price History

Full chart

Market Stats

Previous Close9.65
Open9.79
Day Range8.73 – 9.79
52-Week Range5.30 – 20.88
Volume17.01K
Market Cap1.21B
P/E (TTM)0.00
Forward P/E0.00
EPS-5.78
Dividend Yield0.00%
Beta0.63
50-Day Avg16.20
200-Day Avg10.25

About

Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company' preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Michael I. Halstead J.D.
  • Employees100
  • Headquarters100 King Street West, Toronto, ON, Canada, M5X 1C9, Canada
  • Websitehttps://www.helus.com

Leadership

  • Mr. Eric So L.L.B.Co-Founder, President & Executive Chairman · b. 1976
  • Mr. Paul GlavineCo-Founder, Chief Growth Officer & Director · b. 1989
  • Mr. Greg CaversChief Financial Officer · b. 1971
  • Mr. Aaron BartloneChief Operating Officer · b. 1967
  • Dr. Amir Inamdar FFPM, MBBSChief Medical Officer · b. 1974
  • Mr. Michael I. Halstead J.D.CEO & Director · b. 1973
  • Mr. John KanakisCo-Founder · b. 1980
  • Dr. Alex L. Nivorozhkin Ph.D.Chief Scientific Officer · b. 1960
  • Ms. Lori ChallengerChief Compliance, Ethics & Administrative Officer
  • Mr. Gabriel FahelChief Legal Officer & Corporate Secretary · b. 1976

Financials

Income Statement

Currency: USD2022-03-312023-03-312024-03-312025-03-312026-03-31
Total Revenue00000
Cost of Revenue0----
Gross Profit0----
Operating Expense63.84M----
Operating Income-63.84M-51.52M-78.84M-103.13M-142.59M
EBITDA--51.27M-78.41M-102.78M-142.47M
Net Income-67.63M-47.49M-78.08M-81.61M-148.00M
R&D17.59M25.49M32.36M39.21M86.59M
Interest Expense0----

Balance Sheet

Currency: USD2022-03-312023-03-312024-03-312025-03-312026-03-31
Total Assets84.06M53.90M302.02M258.62M251.17M
Total Liabilities7.91M5.66M10.10M21.42M19.38M
Total Equity76.16M48.23M291.93M237.20M231.79M
Cash53.64M16.63M208.99M135.02M157.26M

Cash Flow

Currency: USD2022-03-312023-03-312024-03-312025-03-312026-03-31
Operating Cash Flow-45.21M-47.43M-68.91M-72.33M-133.27M
Financing Cash Flow35.78M13.56M254.51M14.10M198.24M
Capital Expenditure520.00K3.31M710.00K1.40M1.37M
Free Cash Flow-45.73M-50.74M-69.62M-73.72M-134.64M
FCF to OCF101.15%106.98%101.03%101.93%101.03%

Earnings

Report DateFeb 15, 2021Aug 13, 2021Nov 15, 2021Feb 10, 2022Jun 22, 2022Nov 14, 2022Feb 14, 2023Aug 14, 2023Nov 13, 2023Feb 14, 2024Aug 8, 2024Nov 13, 2024Feb 10, 2025Jun 30, 2025Nov 13, 2025Feb 13, 2026Jun 29, 2026Aug 14, 2026Nov 12, 2026
EPS Estimate-0.76-1.77-3.17-3.32-3.04-2.85-2.66-2.13-1.77-1.37-1.33-0.91-1.57-1.23-1.33-0.98-1.14-1.38-0.95
EPS Actual-3.80-3.40-3.89-3.65-3.65-2.09-2.28-2.66-1.90-3.42-0.76-2.86-0.53-1.46-1.65-1.36-1.21-1.26-
Surprise-400.00%-92.09%-22.71%-9.94%-20.07%26.67%14.29%-24.88%-7.34%-149.63%42.86%-214.29%66.24%-18.70%-24.06%-38.78%-6.14%8.70%-
TimingAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap1.21B
Enterprise Value1.28B
Trailing P/E0.00
Forward P/E0.00
Price / Sales16423.93
Price / Book3.98
EPS-5.78
Book Value5.51
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-166.94M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-86.94%
Return on Assets-44.38%
Shares Outstanding73.06M
Shares Float58.56M
Beta0.63
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Sep 19, 20241:38